http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2571872-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbe1d40faa1ed62003e4b49d8b278688 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-538 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 |
| filingDate | 2011-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_415f3a0042f0adac4ee220afe18e498f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46b10f203098711602b4b7d81d3d270b |
| publicationDate | 2013-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2571872-A1 |
| titleOfInvention | Compounds |
| abstract | A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR 6 or O; A 1 and A 2 are independently hydrogen or C 1-6 alkyl or may together form a carbonyl group; R 1 and R 2 are independently hydrogen, halogen, CF 3 , CN, OR 7 , OR 8 , NR 8 R 9 , NR 8 COR 10 , NR 8 S0 2 R 10 , S0 2 NR 8 R 9 , SO 2 R 10 or C 1-6 alkyl optionally and independently substituted by one or more of hydroxyl, C 1-6 alkoxy, halogen or NR 8 R 9 ; R 3 is hydrogen, halogen, CF3 or OR 7; R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9; or when R 3 and R 4 are positioned ortho and taken together form -0(CH 2 ) m O-, where m is 1-3; R 5 is hydrogen or C 1-6 alkyl optionally substituted by hydroxyl, C 1-6 alkoxy or NR 8 R 9 ; R 6 is hydrogen or C 1-6 alkyl; R 7 is hydrogen or C 1-6 alkyl optionally substituted by OR 8 or NR 8 R 9 ; R 8 is hydrogen, C 1-6 alkyl, optionally substituted by hydroxyl or C 1-6 alkoxy or C 1-3 alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C 1-6 alkyl, CF 3 , OR 7 , NR 8 R 9 or OCF 3 ; or the groups R 8 and R 9 when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR 7 , S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C 1-6 alkoxy; or the groups R 8 and R 9 when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C 1-6 alkoxy; and R 10 is C 1-6 alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C 1-6 alkyl, CF 3 , OCF 3 or OR 7 ; and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed. |
| priorityDate | 2010-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 878.